This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 25 open trials
Oxford pre-cancerous disorders study (OxPLoreD)
This study aims to uncover new biological markers which help identify patients who are more likely to develop myeloma by observing and monitoring patients with non-cancerous disorders, MGUS (monoclonal gammopathies of undetermined significance), Waldenstroms Macroglobulinaemia (WM) and Smouldering Myeloma (SM).
Churchill Hospital, Oxford
Who can enter the study?:
Patients with IgM, IgA or IgG MGUS, smouldering myeloma or non-symptomatic Waldenstrom’s Macroglobulinaemia who have been diagnosed in the last two years.
Patients will be studied for up to 5 years.
Patients will be required to:
(for Medical Professionals):
This observational study to identify clinical, genomic and immunological predictive markers of progression to malignant disease. The study is open to patients diagnosed in the last 2 years with early-stage Chronic Lymphocytic Leukaemia (CLL), Monoclonal B-cell Lymphocytosis (MBL), Monoclonal Gammopathy of Uncertain Significance (MGUS), asymptomatic Waldenstroms Macroglobulinaemia (WM) and Smouldering Myeloma (SM). For more information, click here.